Notice: This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesOwnershipTrends VACC vs. ZNTL, NLTX, CKPT, SLN, MNPR, IFRX, PBYI, CRBP, BMEA, and VTYXShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Zentalis Pharmaceuticals (ZNTL), Neoleukin Therapeutics (NLTX), Checkpoint Therapeutics (CKPT), Silence Therapeutics (SLN), Monopar Therapeutics (MNPR), InflaRx (IFRX), Puma Biotechnology (PBYI), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical preparations" industry. Vaccitech vs. Zentalis Pharmaceuticals Neoleukin Therapeutics Checkpoint Therapeutics Silence Therapeutics Monopar Therapeutics InflaRx Puma Biotechnology Corbus Pharmaceuticals Biomea Fusion Ventyx Biosciences Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Is ZNTL or VACC more profitable? Zentalis Pharmaceuticals has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -43.91% -34.96% Vaccitech -409.18%-23.41%-20.85% Do institutionals and insiders hold more shares of ZNTL or VACC? 26.1% of Vaccitech shares are held by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Vaccitech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, ZNTL or VACC? Vaccitech has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis PharmaceuticalsN/AN/A-$292.19M-$2.49-0.89Vaccitech$13.42M2.90$5.34M-$1.43-0.71 Which has more risk and volatility, ZNTL or VACC? Zentalis Pharmaceuticals has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Does the MarketBeat Community believe in ZNTL or VACC? Zentalis Pharmaceuticals received 42 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 62.77% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZentalis PharmaceuticalsOutperform Votes5962.77% Underperform Votes3537.23% VaccitechOutperform Votes1770.83% Underperform Votes729.17% Do analysts prefer ZNTL or VACC? Zentalis Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 350.45%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Vaccitech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44Vaccitech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor ZNTL or VACC? In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Vaccitech. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 0 mentions for Vaccitech. Zentalis Pharmaceuticals' average media sentiment score of 0.36 beat Vaccitech's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Zentalis Pharmaceuticals Neutral Vaccitech Neutral SummaryZentalis Pharmaceuticals and Vaccitech tied by winning 8 of the 16 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.93M$6.60B$5.45B$9.27BDividend YieldN/A2.96%5.37%3.98%P/E Ratio-0.714.4057.6913.35Price / Sales2.90339.331,236.0381.94Price / Cash19.3065.0944.3737.67Price / Book0.155.265.094.75Net Income$5.34M$154.64M$117.85M$224.45M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$1.01-6.5%N/A-64.4%$38.93M$13.42M-0.7133ZNTLZentalis Pharmaceuticals2.6025 of 5 stars$2.24-6.3%$10.00+346.4%-83.1%$159.62MN/A-0.90160Analyst ForecastNews CoveragePositive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$16.60-5.8%N/A-48.1%$156.01MN/A-5.3490High Trading VolumeCKPTCheckpoint Therapeutics3.8424 of 5 stars$3.18-4.5%$12.00+277.4%+78.6%$155.28M$100,000.00-1.7310SLNSilence Therapeutics2.0512 of 5 stars$5.12+1.8%$57.20+1,017.2%-70.2%$153.24M$31.55M-3.26100High Trading VolumeMNPRMonopar Therapeutics1.4087 of 5 stars$28.54-6.4%$38.50+34.9%+2,158.8%$150.69MN/A-14.4910Analyst ForecastAnalyst RevisionNews CoverageIFRXInflaRx2.2891 of 5 stars$2.54-0.4%$8.00+215.0%+46.3%$149.56M$70,000.00-2.3560PBYIPuma Biotechnology4.2819 of 5 stars$2.97-1.7%$7.00+135.7%-40.8%$145.79M$243.57M6.19200Analyst RevisionCRBPCorbus Pharmaceuticals4.0653 of 5 stars$11.92-9.1%$62.00+420.1%+39.7%$145.19MN/A-2.5440BMEABiomea Fusion2.3761 of 5 stars$3.97-2.2%$39.36+891.5%-70.6%$143.87MN/A-0.9950VTYXVentyx Biosciences2.791 of 5 stars$2.02+6.9%$10.00+395.0%+14.8%$142.83MN/A-0.8630 Related Companies and Tools Related Companies Zentalis Pharmaceuticals Competitors Neoleukin Therapeutics Competitors Checkpoint Therapeutics Competitors Silence Therapeutics Competitors Monopar Therapeutics Competitors InflaRx Competitors Puma Biotechnology Competitors Corbus Pharmaceuticals Competitors Biomea Fusion Competitors Ventyx Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VACC) was last updated on 1/25/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
